Grants and Contributions:
The investment will enable the retention and growth of Medicago’s unique Canadian technology and IP in Canada and will invest in and expand this critical element of plant-based VLP vaccine technology development and supply chain, contributing to Canada’s pandemic preparedness goals.
Please note this update includes a change to improve standardization of reporting across projects. The end date was updated from (30/04/2043) to the current end date of (30/04/2046). This is not an extension. The end date now reflects the entirety of the agreement duration, including the benefit phase and residual audit period.
Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services; Facilitate the growth and expansion of firms in Canada; Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.